Repression of intestinal drug metabolizing enzymes by the SV40 large T antigen

M T Sáenz-Robles1, D Toma, P Cantalupo

  • 1Department of Biological Sciences, University of Pittsburgh, Pittsburgh, PA 15260, USA.

Oncogene
|March 6, 2007
PubMed

Insights

The SV40 large T antigen (TAg) in intestinal cells lowers detoxification enzymes, impacting carcinogen and drug metabolism. This suggests a functional retinoblastoma pathway is vital for intestinal detoxification.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Toxicology

Background:

  • Detoxification enzymes and transporters in the liver and small intestine eliminate toxic compounds like carcinogens.
  • The SV40 large T antigen (TAg) is a viral protein known to interfere with cellular processes.

Purpose of the Study:

  • To investigate the effect of SV40 large T antigen (TAg) expression on detoxification systems in intestinal epithelial cells.
  • To determine the role of the retinoblastoma (Rb) pathway in TAg-mediated suppression of detoxification enzymes.

Main Methods:

  • Comparison of mRNA levels for drug metabolizing/detoxifying enzymes and transporters in TAg-expressing intestinal cells versus non-transgenic littermates.
  • Assessment of TAg's ability to block xenobiotic induction of these mRNAs.
  • Analysis of the role of the LXCXE motif in TAg and its interaction with the Rb family of tumor suppressors.

Main Results:

  • Intestinal epithelial cells expressing TAg showed significantly reduced mRNA levels for key detoxification enzymes and transporters.
  • TAg inhibited the induction of these detoxification-related mRNAs by xenobiotics.
  • The repression was dependent on an intact LXCXE motif in TAg, implicating Rb pathway inactivation.
  • TAg expression in the liver did not suppress P450 enzymes, indicating tissue-specific effects.

Conclusions:

  • A functional retinoblastoma pathway in the intestine is essential for the proper expression of the carcinogen detoxification system.
  • Loss of Rb tumor suppressor function may increase susceptibility to chemical injury in the intestine.
  • TAg-mediated suppression of detoxification enzymes has significant implications for understanding carcinogen and drug metabolism.

Related Concept Videos

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
Drug Metabolism: Phase II Reactions01:14

Drug Metabolism: Phase II Reactions

Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Carrier-Mediated Transport01:06

Carrier-Mediated Transport

Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Size and Structure of Viral Genomes01:26

Size and Structure of Viral Genomes

Viral genomes exhibit remarkable diversity in size, structure, and composition, influencing their replication strategies and interactions with host cells. These genomes consist of either DNA or RNA and may be linear or circular. Additionally, they can be single-stranded or double-stranded, with each configuration affecting how the virus propagates within a host. RNA viruses, for instance, generally have smaller genomes than DNA viruses, a factor that contributes to their high mutation rates and...